
Cancer treatment costs expected to skyrocket by 62 percent in the next ten years, which will obviously minimize the survival rates, reveals a new study.
Healthcare analysts Laing and Buisson claimed that the costs are likely to go up from 9.4billion pounds in 2010 to 15.3billion pounds by 2021.
Advertisement
It implies that the average cost of treating a cancer patient will increase from 30,000 pounds in 2010 to 40,000 pounds in 2021.
The leap is primarily because of Britain's ageing population, which is predicted to lead to a 20 per cent growth in cancer rates by 2021.
Other factors include the rising costs of treatments and technology.
"If we do not address the rising cost of cancer, we are unlikely to be able to afford the desired and expected level of cancer diagnosis and treatment over the next 10 years and beyond," The Cancer Diagnosis and Treatment: A 2021 Projection report, carried out for private healthcare firm Bupa, said.
"This possibility will mean that the UK's cancer survival rate could fall even further behind that of other developed countries," the report added.
Source: ANI
Other factors include the rising costs of treatments and technology.
Advertisement
"If we do not address the rising cost of cancer, we are unlikely to be able to afford the desired and expected level of cancer diagnosis and treatment over the next 10 years and beyond," The Cancer Diagnosis and Treatment: A 2021 Projection report, carried out for private healthcare firm Bupa, said.
"This possibility will mean that the UK's cancer survival rate could fall even further behind that of other developed countries," the report added.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

More affected relatives, higher lung cancer risk; participants with affected mothers or siblings faced increased risk.

Colorectal cancer can be lowered by up to 7% by increasing dietary consumption of folate rich foods like spinach, broccoli or taking folate supplements.

The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.

The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.

A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.